ArticleClinical lipidology2011
Lysophosphatidic acid effects on atherosclerosis and thrombosis.
Article in Clinical lipidology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 56 citations in OpenAlex.
- Lysophosphatidic acid: a promising biomarker for diagnosing sepsis and predicting in-hospital mortality.Frontiers in immunology · 2025Article
- Melatonin and TGF-β-Mediated Release of Extracellular Vesicles.Metabolites · 2023Review
- The Autotaxin-LPA Axis Emerges as a Novel Regulator of Smooth Muscle Cell Phenotypic Modulation during Intimal Hyperplasia.International journal of molecular sciences · 2023Article
- Lysophosphatidic Acid Promotes Epithelial-Mesenchymal Transition in Kidney Epithelial Cells via the LPAR1/MAPK-AKT/KLF5 Signaling Pathway in Diabetic Nephropathy.International journal of molecular sciences · 2022Article
- Autotaxin Activity in Chronic Subdural Hematoma: A Prospective Clinical Study.Diagnostics (Basel, Switzerland) · 2022Article
- Crocin ameliorates atherosclerosis by promoting the reverse cholesterol transport and inhibiting the foam cell formation via regulating PPARγ/LXR-α.Cell cycle (Georgetown, Tex.) · 2022Article
- Preventing the Increase in Lysophosphatidic Acids: A New Therapeutic Target in Pulmonary Hypertension?Metabolites · 2021Article
- Lysophosphatidic acid species are associated with exacerbation in chronic obstructive pulmonary disease.BMC pulmonary medicine · 2021Article
- Disrupted Blood-Brain Barrier and Mitochondrial Impairment by Autotaxin-Lysophosphatidic Acid Axis in Postischemic Stroke.Journal of the American Heart Association · 2021Article
- Mechanosensitive smooth muscle cell phenotypic plasticity emerging from a null state and the balance between Rac and Rho.Cell reports · 2021Article
- Hypercholesterolemia and Lymphatic Defects: The Chicken or the Egg?Frontiers in cardiovascular medicine · 2021Review
- TRPV1 expressed throughout the arterial circulation regulates vasoconstriction and blood pressure.The Journal of physiology · 2020Article
- Review
- Lysophosphatidic acid acts on LPABritish journal of pharmacology · 2018Article
- Lysophosphatidic Acid Promotes Expression and Activation of Matrix Metalloproteinase 9 (MMP9) in THP-1 Cells via Toll-Like Receptor 4/Nuclear Factor-κB (TLR4/NF-κB) Signaling Pathway.Medical science monitor : international medical journal of experimental and clinical research · 2018Article
- CD14 is a key mediator of both lysophosphatidic acid and lipopolysaccharide induction of foam cell formation.The Journal of biological chemistry · 2017Article
- mTOR signaling promotes foam cell formation and inhibits foam cell egress through suppressing the SIRT1 signaling pathway.Molecular medicine reports · 2017Article
- CRE and SRE mediate LPA-induced CCN1 transcription in mouse aortic smooth muscle cells.Canadian journal of physiology and pharmacology · 2017Article
- Lysophospholipids and their G protein-coupled receptors in atherosclerosis.Frontiers in bioscience (Landmark edition) · 2016Review
- Matricellular protein Cyr61 bridges lysophosphatidic acid and integrin pathways leading to cell migration.The Journal of biological chemistry · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Lysophosphatidic acid (LPA) has been found to accumulate in high concentrations in atherosclerotic lesions. LPA is a bioactive phospholipid produced by activated platelets and formed during the oxidation of LDL. Accumulating evidence suggests that this lipid mediator may serve as an important risk factor for development of atherosclerosis and thrombosis. The role of LPA in atherogenesis is supported by the evidence that LPA: stimulates endothelial cells to produce adhesion molecules and chemoattractants; induces smooth muscle cells to produce inflammatory cytokines; stimulates smooth muscle cell dedifferentiation, proliferation, and migration; increases monocyte migration and decreases monocyte-derived cell emigration from the vessel wall; induces hypertension and vascular neointimal formation in vivo; and promotes plaque progression in a mouse atherosclerosis model. The role of LPA in thrombogenesis is supported by the evidence that LPA markedly induces the aggregation of platelets and the expression of tissue factor, which is the principal initiator of blood coagulation. Recent experimental data indicate that LPA is produced by specific enzymes and that LPA binds to and activates multiple G-protein-coupled receptors, leading to intracellular signaling. Therapeutics targeting LPA biosynthesis, metabolism and signaling pathways could be viable for prevention and treatment of atherosclerosis and thrombosis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.